Pancreatic Cancer

The list below will be continuously updated.

Alpha-lipoic acid + low-dose naltrexone: Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases. http://www.ncbi.nlm.nih.gov/pubmed/20042414

Dipyridamole 

Chloroquine see also my post on Chloroquine.

Biological Approaches to Therapy of Pancreatic Cancer http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882228/

A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumorshttp://www.ncbi.nlm.nih.gov/pubmed/24647860

Celecoxib and GABA cooperatively prevent the progression of pancreatic cancer in vitro and in xenograft models of stress-free and stress-exposed mice. http://www.ncbi.nlm.nih.gov/pubmed/22916251

Celecoxib & Metformin & 2DG
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation http://www.nature.com/bjc/journal/v111/n1/full/bjc2014272a.html “The most glycolytic pancreatic cancer cell line was exquisitely sensitive to 2-DG, whereas the least glycolytic pancreatic cancer cell was resistant to 2-DG. However, when combined with metformin, inhibitor of mitochondrial respiration and activator of AMP-activated protein kinase, 2-DG synergistically enhanced ATP depletion and inhibited cell proliferation even in poorly glycolytic, 2-DG-resistant pancreatic cancer cell line. Furthermore, treatment with conventional chemotherapeutic drugs (e.g., gemcitabine and doxorubicin) or COX-2 inhibitor, celecoxib, sensitised the cells to 2-DG treatment.”

Metformin: How diabetes drug metformin inhibits progression of pancreatic cancer http://www.sciencedaily.com/releases/2016/01/160114121730.htm

Paricalcitol: Does Vitamin D fight pancreatic cancer? http://www.utsandiego.com/news/2014/sep/25/pancreatic-cancer

Octreotide is a monthly injection (a bit more expensive) used at German clinics to slow down or stop the growth of pancreatic cancer as well as other cancers.

Propranolol: Î²2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFκB and AP-1. http://www.ncbi.nlm.nih.gov/pubmed/20424515

VT-122, made by Vicus Therapeutics, is a drug combining two widely accessible drugs propranolol and etodolac believed to damp tumor-promoting inflammation and restore immune surveillance and as a result it may significantly improve outcomes for pancreatic cancer patients.
Promising clinical trial results have been published with VT-122 in pancreatic cancer http://meetinglibrary.asco.org/content/140626-158
Neural Regulation of Pancreatic Cancer: A Novel Target for Intervention http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586771/

Curcumin: Phase II trial of curcumin in patients with advanced pancreatic cancer http://www.ncbi.nlm.nih.gov/pubmed/18628464

Vitamin A: Vitamin A may help improve pancreatic cancer chemotherapy https://www.sciencedaily.com/releases/2016/05/160524085950.htm

The enzymes involved in the TCA cycle and glutaminolysis significantly contribute to cancer cell proliferation, particularly in case of pancreatic cancer http://journal.frontiersin.org/article/10.3389/fphys.2017.00217/full
According to this study mito inhibitors are very relevant in Pancraetic cancer. Mitochondria inhibitors widely available are Metformin, Doxycicline, Meclizine but also the less available substance, Salinomycin.

Anti Cholesterol Strategy

Cholesterol is produced within the cells or absorbed by the cell from the blood. When there is too much cholesterol, the cell stores that as lipid droplets. Cholesterol is extremely important for most of the cancer cells including pancreatic cells, and interfering with various intracellular production or store mechanism an help fight cancer. Here are a few links supporting that statement:
We found that the use of simvastatin and atorvastatin after cancer diagnosis is associated with longer survival in patients with nonmetastatic pancreatic adenocarcinoma.
Statins & Metformin Help Pancreatic Cancer Patients
Synergistic Antiproliferative Effects of Zoledronic Acid and Fluvastatin on Human Pancreatic Cancer Cell Lines: An in Vitro Study
STATINS ASSOCIATED WITH 56% REDUCTION OF PANCREATIC CANCER RISK IN MEN
Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer
Research points to a new treatment for pancreatic cancer
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells
etc.

In line with the idea of seeing cholesterol as a weak spot in cancer cells, I developed a treatment strategy to address as many aspects of cholesterol production and trafficking in cancer cells: https://www.cancertreatmentsresearch.com/reduce-cholesterol-in-cancer-cells-to-fight-cancer/ combining Dipyridamole, Statins, Metformin and others into once drug/supplement cocktail approach.

Mebendazole: Here we show that anthelmintics are also cytotoxic to pancreatic and lung cancer cells. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171052#pone.0171052.ref043

Other non-benzimidazole antihelmintic drugs identified in the screens, which may also be of interest for further studies as anticancer agents, include pyrvinum pamoate, hycanthone and niclosamidehttp://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171052#pone.0171052.ref043

Cardiac glycosides (digoxin, lanatoside C, proscilaridin A) and their aglycones (digoxigenin, digitoxigenin) exhibited strong cytotoxic effects (HTS score ≥ 0.9) in both A549 and PANC-1 cells. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171052#pone.0171052.ref043

The subsequent dose-response analysis of auranofin revealed a moderate cytotoxicity with IC50 values of 6.65 and 2.25 μM in A549 and PANC-1 cells, respectively, with a very steep dose-response curve in A549 cells, which potentially reduces its utility as an anticancer agent. Nevertheless, its higher potency against the more chemoresistant PANC-1 cell line warrants attention, particularly given the poor success of existing treatment regimens for pancreatic cancer. http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0171052#pone.0171052.ref043

Disclaimer:

This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, I provide general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. I am not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site. This is just my own personal opinion regarding what we have learned on this road.

Related Articles


Leave a Reply

Please Login to comment
avatar
  Subscribe  
Notify of